Type 2 5′ deiodinase enzyme was observed in both thyroid and eye muscle tissues, highlighting its possible role as a common antigen in thyroid-associated ophthalmopathy. Sera of 105 Graves’ patients and 40 controls, and immunized guinea pig sera against TCSS peptide, showing homology to the amino acid sequence from 132 to 152 of type 2 5′ deiodinase, were investigated to demonstrate the binding effects to human thyroid, eye and skeletal muscle tissues.
Twenty-two Graves’ patients were positive for anti-TCSS peptide antibodies, of whom 18 cases had ophthalmopathy. The levels of anti-TCSS peptide antibodies were higher not only in Graves’ patients with (P<0.0001) and without (P<0.036) eye symptoms compared to controls but also the difference was significant between patients with and without ophthalmopathy (P<0.049). In Western blot, immunized sera showed binding reactions to the supernatant fractions of human thyroid, eye and skeletal muscle tissues at the range of 29 kDa. Patient sera with Graves’ ophthalmopathy resulted in positive reactions directed to membrane areas in thyroid follicular cells, and to fibers in eye and skeletal muscles using immunohistochemical method, while no positive staining was present after adding control sera. The binding features of immunized guinea pig sera exhibited similar staining in all human tissues but could be blocked with Graves’ sera. Our results suggest that type 2 5′ deiodinase enzyme protein could play a role as an antigen in Graves’ disease. Immunized guinea pig sera against TCSS peptide exhibited similar binding reactions and stainings to human thyroid, eye and skeletal muscle tissues as patient sera with Graves’ ophthalmopathy.
Similar content being viewed by others
REFERENCES
Bahn RS: Clinical Review 157. Pathophysiology of Graves’ ophthalmopathy. The cycle of disease. J Clin Endocrinol Metab 88:1939–1946, 2003
Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A: Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385–392, 2002
Takashi Y, Akira S, Ichiro K, Takeo N, Yoshiharu I, Akira T, Sumiya E, Yoshiya T: An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves’ disease. J Clin Endocrinol Metab 85:2775–2778, 2000
Kumar S, Coenen MJ, Scherer PE, Bahn RS: Evidence for enhanced adipogenesis in the orbits of patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 89:930–935, 2004
Mizokami T, Salvi M, Wall JR: Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? J Endocrinol Invest 27:221–229, 2004
Kromminga A, Hagel C, Arndt R, Schuppert F: Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: A possible autoantigenic link in Graves’ patients. J Clin Endocrinol Metab 83:2817–2823, 1998
Gunji K, De Bellis A, Kubota S, Swanson J, Wengrowicz S, Cochran B, Ackrell BAC, Salvi M, Bellastella A, Bizzarro A, Sinisi AA, Wall JR: Serum antibodies against the flavoprotein subunit of eye muscle autoimmunity in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 84:1255–1262, 1999
Gunji K, De Bellis A, Li AW, Yamada M, Kubota S, Ackrell B, Wengrowicz S, Bellastella A, Bizzarro A, Sinisi A, Wall JR: Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: Autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 85:1641–1647, 2000
De Bellis A, Sansone D, Coronella C, Conte M, Iorio S, Perrino S, Battaglia M, Bellastella G, Wall JR, Bellastella A, Bizzarro A: Serum anibodies to collagen XIII: A futher good marker of active Graves’ ophthalmopathy. Clin Endocrinol 62:24–29, 2005
Gopinath B, Musselman R, Adams CL, Tani J, Beard N, Wall JR: Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves’ disease with and without ophthalmopathy: Correlation with clinical features. Thyroid 16:967–974, 2006.
Tani J, Wall JR: Autoimmunity against eye-muscle antigens may explain thyroid-associated ophthalmopathy. CMAJ 175:239–241, 2006
Salvatore D, Tu H, Harney JW, Larsen PR: Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest 98:962–968, 1996
Hosoi Y, Murakami M, Mizuma H, Ogiwara T, Imamura M, Mori M: Expression and regulation of type II iodothyronine deiodinase in cultured human skeletal muscle cells. J Clin Endocrinol Metab 84:3293–3300, 1999
Croteau W, Davey JC, Galton VA, Germain LSt: Cloning of the mammalian type II iodothyronine deiodinase. J Clin Invest 98:405–417, 1996
Merrifield RB: The synthesis of a tetrapeptide. Solid phase peptide synthesis. J Am Chem Soc 85:2149–2154, 1963
Matsueda GR, Stewart JM: A p-ethylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides. Peptides 2:45–50, 1981
Sakakibara S, Shimonishim Y, Kishida Y, Okada M, Sugihara K: Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. Bull Chem Soc Jpn 40:2164–2167, 1967
Werner SC: Modification of classification of eye changes of Graves’ disease: Recommendations of the Ad Hoc Committee of American Thyroid Association. J Clin Endocrinol Metab 44:2034, 1977
Mourits PM, Prummel ME, Wiersinga WM, Kornneef L: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxford) 47:9–14, 1997
Bradford MM: A rapid and sensitive method for the qualification of microgram quantites of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254, 1976
Molnar I., Kaczur V., Boros A., Krajczar G., Balzs C.: IgA autoantibodies against human eye muscle antigen detected by Western blotting and immunohistochemical methods in Graves’ disease. J Endocrinol Invest 18:408–414, 1995
Darras VM, Hume R, Visser TJ: Regulation of thyroid hormone metabolism during fetal development. Mol Cell Endocrinol 151:37–47, 1999
Köhrle J: Local activation and inactivation of thyroid hormones: The deiodinase family. Mol Cell Endocrinol 151:103–119, 1999
Molnar I, Csathy L: Autoantibodies against the type 2 5′-deiodinase are involved in the development of Graves’ ophthalmopathy. In Program of 12th international Thyroid Congress, Kyoto, Japan, p 176 (Abstract), 2000
Nakahara R, Tsunekawa K, Yabe S, Nara M, Seki K, Kasahara T, Ogiwara T, Nishino M, Kobayashi I, Murakami M: Association of antipitiutary antibody and type 2 iodothyronine deiodinase antibody in patients with autoimmune thyroid disease. Endocrinol J 52:691–699, 2005
Stadtman TC: Selenoproteins—tracing the role of a trace element in protein function. PloS Biol 3:2077–2079, 2005
Gereben B, Goncalves C, Harney JW, Larsen PR, Bianco AC: Selective proteolysis of human type 2 deiodinase: A novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol 14:1697–1708, 2000
Zeöld A, Pormüller L, Dentice M, Harney JW, Curcio-Morelli C, Tente SM, Bianco AC, Gereben B: Metabolic instability of type 2 deiodinase is transferable to stable proteins independently of subcellular localization. J Biol Chem 281:31538–31543, 2006
Burmeister LA, Pachucki J, St. Germain DL: Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre- and posttranslational mechanisms. Endocrinology 138:5231–5237, 1997
Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR: Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme’s active center. Endocrinology 141:1127–1135, 2000
Kaminski HJ, Li Z, Richmonds C, Ruff RL, Kusner L: Susceptibility of ocular tissues to autoimmune diseases. Ann NY Acad Sci 998:362–374, 2003
Andrikoula M, Tsatsoulis A: The role of FAS-mediated apoptosis in thyroid disease. Eur J Endocrinol 144:561–568, 2001
Pittoni V, Valesini G: The clearence of apoptotic cells: Implications for autoimmunity. Autoimmunity Rev 1:154–161, 2002
Salvatore D, Bartha T, Harney JW, Larsen PR: Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 137:3308–3315, 1996
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
MolnÁr, I., Szombathy, Z., KovÁcs, I. et al. Immunohistochemical Studies Using Immunized Guinea Pig Sera with Features of Anti-Human Thyroid, Eye and Skeletal Antibody and Graves’ Sera. J Clin Immunol 27, 172–180 (2007). https://doi.org/10.1007/s10875-006-9063-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-006-9063-x